We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Synthorx Inc | NASDAQ:THOR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 67.99 | 67.00 | 67.99 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2019
Synthorx, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-38756 | 46-4709185 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
11099 N. Torrey Pines Road, Suite 190 La Jolla, California |
92037 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (858) 750-4789
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
Common Stock, par value $0.001 per share | THOR | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 |
Other Matters. |
On November 9, 2019, certain members of the management team of Synthorx, Inc. (the Company) will be presenting two posters (the THOR-707 Poster and the IL-10 Poster) at the Society for Immunotherapy of Cancer 2019 Annual Meeting & Pre-Conference. A copy of the THOR-707 Poster is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the IL-10 Poster is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
On November 10, 2019, certain members of the management team of the Company will be presenting a poster (the THOR-809 Poster) at the American College of Rheumatologys 2019 Annual Meeting. A copy of the THOR-809 Poster is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Description |
|
99.1 | THOR-707 Poster, dated November 9, 2019. | |
99.2 | IL-10 Poster, dated November 9, 2019. | |
99.3 | THOR-809 Poster, dated November 10, 2019 |
Forward-Looking Statements
Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Words such as believe, may, will, estimate, promise, plan, continue, anticipate, intend, expect, potential and similar expressions (including the negative thereof) are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from the Companys expectations. Factors that could cause actual results to differ materially from those stated or implied by the Companys forward-looking statements are disclosed in the Companys filings with the Securities and Exchange Commission, including in the section captioned Risk Factors in the Companys Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019. These forward-looking statements represent the Companys judgment as of the time of this report. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Synthorx, Inc. | ||||||
Dated: November 8, 2019 | By: |
/s/ Laura Shawver |
||||
Laura Shawver, Ph.D. | ||||||
President and Chief Executive Officer |
1 Year Synthorx Chart |
1 Month Synthorx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions